Immatics News

Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships

TipRanksMar 29 04:26 ET

Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)

TipRanksMar 24 21:50 ET

Buy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnerships

TipRanksMar 6 23:59 ET

Positive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh's Recommendation

TipRanksNov 20, 2023 01:46 ET

Immatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming Catalysts

TipRanksNov 16, 2023 07:22 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cormedix (CRMD), Immatics (IMTX) and Johnson & Johnson (JNJ)

TipRanksNov 14, 2023 21:10 ET

Positive Clinical Phase 1b Results and Robust Financial Position Boost Immatics (IMTX) to a 'Buy' Rating

TipRanksNov 9, 2023 14:14 ET

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Immatics (IMTX)

TipRanksNov 8, 2023 22:20 ET

Immatics Analyst Ratings

BenzingaNov 2, 2023 08:58 ET

Analysts Offer Insights on Healthcare Companies: Ovid Therapeutics (OVID), Lantheus (LNTH) and Immatics (IMTX)

TipRanksOct 19, 2023 08:20 ET

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Omega Therapeutics (OMGA) and Roivant Sciences (ROIV)

TipRanksSep 27, 2023 09:40 ET

Immatics (IMTX) Receives a Buy From Mizuho Securities

TipRanksSep 12, 2023 11:35 ET

Mizuho Securities Keeps Their Buy Rating on Immatics (IMTX)

TipRanksAug 18, 2023 08:45 ET

Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), CVS Health (CVS)

TipRanksAug 18, 2023 05:30 ET

Chardan Capital Sticks to Their Buy Rating for Immatics (IMTX)

TipRanksAug 17, 2023 16:45 ET

Immatics (IMTX) Gets a Buy From Mizuho Securities

TipRanksMay 17, 2023 23:55 ET

Jefferies Keeps Their Buy Rating on Immatics (IMTX)

TipRanksMay 17, 2023 08:26 ET

SVB Securities Keeps Their Buy Rating on Immatics (IMTX)

TipRanksMay 5, 2023 11:28 ET

Immatics Initiated Buy at Mizuho on Underrated TCR Opportunity

Seeking AlphaMar 31, 2023 13:47 ET

Mizuho Initiates Coverage On Immatics With Buy Rating, Announces Price Target of $12

BenzingaMar 31, 2023 04:38 ET